SEARCH

SEARCH BY CITATION

Keywords:

  • hepatocellular carcinoma;
  • TOP2A;
  • biomarker;
  • chemosensitization

Abstract

  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information

Genomic gain represents an important mechanism in the activation of proto-oncogenes. In many instances, induced oncogenes hold clinical implications both as prognostic markers and targets for therapeutic design. In hepatocellular carcinoma (HCC), although chromosomal gains are common, information on underlying oncogenes induced remains minimal. Here, we examined 7 causal sites of HCC for overexpressed genes by array-based transcriptional mapping. In 22 HCC cell lines and early passages of cultures studied, clusters of up-regulated genes were indicated, where TOP2A expression ranked the highest. Distinct TOP2A transcriptions were confirmed in an independent series of HCC tumors relative to adjacent non-tumoral liver (p = 0.0018). By tissue microarray analysis of 172 HCC, we found TOP2A expressions correlated with advance histological grading (p < 0.001), microvascular invasion (p = 0.004) and an early age onset of the malignancy (≤40 years; p = 0.007). In conjunction with P-gp and MRP1, TOP2A were further assessed for its association with chemotherapy responsiveness and survival in 148 patients who entered our recently reported Phase III prospective randomized study. In 73 chemoresistant and 75 nonresistant patients, only TOP2A positivity correlated with chemoresistance (p = 0.029) and shorter patients survival (p < 0.0001). The potential therapeutic value in targeting TOP2A by Etoposide, as a single agent, and in combination with Doxorubicin was also explored. In vitro cytotoxic studies suggested Etoposide at IC20 readily reduced IC50 values of Doxorubicin by a magnitude of ∼3.5 to 10-fold compared to Doxorubicin alone (p < 0.028). Our study highlighted for the first time the prognostic value of TOP2A in HCC and the potential use of TOP2A reactive agents in therapy. © 2008 Wiley-Liss, Inc.

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer morbidity and mortality in Southeast Asia and China1, 2 and in the United States, where its incidence has increased by over 90% over the past 3 decades.3 Curative surgery offers the only hope for long-term survival for individuals diagnosed with HCC. However, by the time of clinical presentation, most patients are at the advanced metastatic stage, which rendered liver resection amenable to only a minority of patients. For the majority of patients, the median survival is ∼6 months.4 Chemotherapy is one of the mainstay treatments for patients with inoperable disease. Unfortunately, the response to chemotherapy has been poor; even with the most effective class of anthracycline-based therapies such as doxorubicin, the reported response rate has been low (<20%).5–7 Moreover, the administration of doxorubicin is often associated with the coexistence of drug resistance and high treatment-related cytotoxicity. The overall dismal outcome thus underscores the urgent need for reliable biomarkers in the diagnosis and prognosis of HCC and improved molecular targets for the development of more efficacious therapies.

In breast cancer, specific amplifications and overexpressions of the HER2/neu oncogene hold predictive value of disease outcome and represent an ideal target for anti-cancer therapy.8, 9 In cancer drug resistance, overexpression of transporters proteins, P-glycoprotein (P-gp)10 and multidrug resistance protein (MRP1),11 have long been implicated in the enhanced cellular drug efflux from the increased transporters activities. In HCC, few oncogenes of prognostic and therapeutic values have been described. The ability to expand our knowledge on proto-oncogenes involved in the malignant development and progression of HCC would undoubtedly improve our understandings on liver carcinogenesis. This information would also permit development of novel therapeutic options as current benefits of most molecular therapies such as Imatinib (tyrosine kinase inhibitor) and Gefitinib (anti-EGFR) aimed at attenuating the overexpressed oncogenic activities.

Regional chromosomal gain is a major mechanism in inducing elevated genes expression. In an effort to define vital cytogenetic events from extraneous alterations linked to tumor complexities, our group has previously conducted large-scale informatic analysis on comparative genomic hybridization (CGH) data that were derived from more than 150 HCC tumors.12 The model established from neural network algorithms suggested genomic gains on chromosomes 1q and 8q in the initial development of HCC, and gains of few chromosomes in association with advanced tumor stages and adverse disease outcome. The SORs of these causal events have been further defined to 1q21-q24, 6p12-p22, 7q21-q31, 8q22-q24, 17q21-q25, 19q13 and 20q12-q13.12–15 As studies on correlating CGH data with transcriptome array have shown that 40–60% of genes in amplified regions are indeed overexpressed,16, 17 in this study, we have attempted to define candidate overexpressed genes in the causal regional gains of HCC. We constructed a gene transcript map from a cohort of 22 HCC cell lines and early passages of cultures that presented gains or amplifications of aberrant loci in 40% to 72% of cases (9∼16 cell lines). A significant enrichment of highly expressed genes was suggested from the high-resolution mapping. Distinct expression of proto-oncogene, TOP2A at chr.17q21, further prompted our investigations for its potential value as biomarker in HCC by TMA analysis. The prognostic value of TOP2A in chemotherapy responsiveness and survival was also examined, in comparison to P-gp and MRP1, in prechemotherapy tumor biopsies of 148 HCC patients who had been entered into our Phase III prospective randomized study for doxorubicin-based therapy.7 The therapeutic value of antitopoisomerase therapy in vitro was also explored. Our study represents the first to highlight the clinical importance of TOP2A in HCC.

Material and methods

  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information

Cell lines

Eight HCC cell lines, HepG2, Hep3B, PLC/PRF/5, SNU387, SNU398, SNU423, SNU449 and SNU475, were obtained from the American Type Culture Collection (ATCC, Rockville, MD). Huh7 cell line was acquired from the Health Science Research Resources Bank (Osaka, Japan). HepG2, Hep3B and PLC/PRF/5 were cultured according to recommendations in DMEM medium containing 10% fetal bovine serum (Gibco BRL, Grand Island, NY), whereas Huh7, SNU387, SNU398, SNU423, SNU449 and SNU475 were maintained in complete RPMI medium (Gibco BRL, Grand Island, NY). Thirteen HCC cell lines HKCI-1, -2, -3, -4, -5, -6, -7, -8, -9, -10 and HKCI-C1, -C2, -C3 were established from our laboratory, eight of which have been previously reported.18–20 Using the same methodology described, we have newly established 5 additional cell lines (HKCI-6, -7, -8, -9 and -10). The HKCI series of cell lines were maintained in RPMI 1640 glutamax with HEPES buffer supplemented with 10% fetal bovine serum, 10 ng/ml selenium, 10 μg/ml transferrin and 10 μg/ml insulin. The early passages (passages 14–25) of the HKCI cell lines were employed in transcriptional mapping, totaling 22 specimens of homogenous HCC cells being studied. All cell lines have also been subjected to conventional CGH analysis20 to define the regional chromosomal aberrations present. All cultures were maintained in a humidified incubator at 37°C in an atmosphere of 5% CO2.

Patients

Tumorous liver and corresponding adjacent non-tumoral liver were collected from 30 patients who underwent curative surgery for HCC at the Prince of Wales Hospital, Hong Kong. Histological examination confirmed the diagnosis of HCC with 76.7% having coexisting cirrhosis. Patients were mostly chronic viral hepatitis B carriers (93.3%).

Randomized phase III clinical study

One hundred and forty-eight patients who entered our reported randomized Phase III clinical study on doxorubicin-based chemotherapy was studied.7 The administration of chemotherapeutic agents was as described.7 Before study entry, the diagnosis of HCC was histologicaly confirmed with tumor biopsy. Patients were separately consented to participate in the present correlative study, which utilized their biopsied samples. The protocol was approved by the Clinical Research Ethics Committee of the Chinese University of Hong Kong. The clinical and demographic characteristics at baseline of patients recruited are shown in Table I. Evaluation of response was conducted by radiological methods after the third and sixth cycles. Classification of response was based on the World Health Organization (WHO) criteria.21 Complete response was defined as no evidence of tumor by clinical and radiological assessments. Partial response was defined as a decrease of ≥50% in cross-perpendicular dimensions of the largest tumor nodule for at least 30 days without the appearance of new lesions or progression of other measurable or evaluable lesions. Stable disease was defined as any response less than a partial response for the largest tumor nodule or an increase in cross-perpendicular dimensions of <25% of any measurable or evaluable lesions, without the appearance of new lesions. Progressive disease was defined as an increase of ≥25% of any measurable or evaluable lesions or the appearance of new lesions.

Table I. Clinical and Demographic Characteristics at Baseline of 148 Patients with Unresectable Hepatocellular Carcinoma
 No. of patients
  • AFP, alfa feto-protein; HBsAg, hepatitis B surface antigen.

  • 1

    Chemotherapy “nonresistant” group = partial response + stable disease; chemotherapy “resistant” group = progressive disease.

Number of patients (male:female)135:13
Median age (years; range)50 (19–71)
Median baseline AFP (ng/ml)2,270 (3–1,892,600)
Coexisting cirrhosis70 (47%)
Viral HBV infection 
 HbsAg positive129 (87%)
 HbsAg negative19 (13%)
1Outcome of chemotherapy 
 Partial response23
 Stable disease52
 Progressive disease73
 Median overall survival7.9 months (range 6.4–10.8)

For the purpose of the present study, patients were categorized into 2 groups. Those whom did not obtain clinical benefit and developed progressive disease were classified as being “chemotherapy resistant” group. Those who obtained clinical benefit by achieving complete response, partial response and stable disease were classified as being “chemotherapy nonresistant” group. The primary endpoint was overall survival from date of randomization. The secondary endpoints were overall response and toxicity.

Transcriptional mapping

A gene transcript map from array profiling was constructed according to our method previously described.19 Briefly, reverse-transcribed RNA from cell lines and normal liver pool were fluorescent-labeled with Cy5-dCTP or Cy3-dCTP. Labeled cDNAs were hybridized onto cDNA arrays (Ontario Cancer Institute, Canada) containing ∼19,000 sequence-verified human genes. The average resolution throughout the genome was ∼100 to 200 kb. Hybridized signals captured by the ScanArray 5000 (Packard BioScience, UK) were analyzed by the GenePix Pro 4.0 (Axon, CA). Data manipulation was facilitated by the Normalization Suite v2.5 (http://www.utoronto.ca/cancyto/). Results from duplicate spots and dye swap experiments were averaged, and signal ratios integrated with physical map location of each cDNA clone. “Test to reference” ratios ≥2-fold were considered increased genes expression.

Quantitative RT-PCR

First strand cDNA was prepared from HCC tumors, adjacent non-tumoral livers and cell lines by random hexanucleotide (Applied Biosystems, Foster City, CA). cDNA preparation mixed with 0.2 μM primers, 4 mM MgCl2, 0.25 mM dNTPs mix and 0.025U AmpliTaq Gold® DNA polymerase (Applied Biosystem, Foster City, CA) was amplified at 94°C for 30 sec, 60°C for 10 sec and 72°C for 10 sec. Primer sequences for TOP2A amplification were forward, 5′-TTCTTGATATGCCCCTTTGG-3′ and reverse, 5′-GCTTCAACAGCCTCCAATTC-3′. The emission intensity was detected by the iCycler detection system (BioRad Laboratories, CA). The amount of TOP2A expression was determined by normalization to endogenous reference (18S RNA). Threshold cycles averaged from triplicate reactions were expressed as a relative ratio between cell lines and normal human liver controls, and between tumors and adjacent nontumoral liver. A value ≥2-fold was considered up-regulation.

Fluorescence in-situ hybridization

TOP2A copy number was studied by dual-color FISH according to method described.19 Human BAC clone RP11-513C18 (Invitrogen, CA) that embodied the TOP2A gene and reference clone RP11-110A23 (Invitrogen, CA) on chr1p31.3 were differentially labeled with biotin-dUTP and digoxigenin-dUTP, respectively. The selection of reference probe was based on our previous CGH study that suggested regional 1p31.3 rarely displayed imbalances in HCC.15 Hybridized probes were visualized by fluorescent-conjugated antibodies and scored for test to reference signal ratios in at least 50 interphase nuclei following nuclear counterstained in DAPI.

Tissue microarray

Formalin-fixed paraffin-embedded archive tissue of 172 paired HCC tumor and adjacent non-tumoral liver were arranged in tissue array blocks. Five-micrometer sections taken from each array block were stained haematoxylin & eosin. Primary antibody against TOP2A (Calbiochem, San Diego, CA) was applied at dilution of 1:60. The specificity of TOP2A antibody was confirmed by blocking analysis using purified human Topoisomerase 2α, 170 kDa (TopoGEN, Port Orange, FL). Chromogen development was performed using the universal HRP Multimer ultraview kit (Ventana medical system, Australia). The scoring of TOP2A expressions was classified as no staining (Grade 1), 1–9% of cells (Grade 2) and >10% of cells (Grade 3). The clinicopathological information of tumor pairs studied is shown in Table II.

Table II. Clinicopathological Parameters of HCC Cases Studied in Tissue Microarray
  1. HBsAg, hepatitis B surface antigen.

Gender 
 Male143 (83.1%)
 Female29 (16.9%)
Age 
 <40 year27 (15.7%)
 >40 year145 (84.3%)
Viral HBV infection 
 HbsAg positive129 (75.0%)
 HbsAg negative43 (25.0%)
Liver cirrhosis 
 Present124 (72.0%)
 Absent48 (28.0%)
Grade of tumor differentiation 
 Well differentiated39 (22.7%)
 Moderately differentiated118 (68.6%)
 Poorly differentiated15 (8.7%)
T staging 
 Stage T1102 (59.3%)
 Stage T242 (24.4%)
 Stage T326 (15.1%)
 Stage T41 (0.6%)
 Macroregenerative nodule1 (0.6%)
Macrovascular invasion 
 Presence14 (8.1%)
 Absence158 (91.9%)
Microvascular invasion 
 Presence57 (33.1%)
 Absence115 (66.9%)
Tumoral lesions 
 Solitary138 (80.2%)
 Multiple34 (19.8%)

Immunohistochemical stainings of TOP2A, P-gp and MRP1

Serial 4 μm sections were obtained from 148 prechemotherapy tumor biopsies embedded in paraffin. Immunohistochemical staining of TOP2A was as described for TMA analysis. Expression of MRP1 (at 1:20 dilution; Alexis Biochemicals, Switzerland) was detected using avidin–biotin-complex method, whereas P-gp (at 1:80 dilution; Alexis Biochemicals, Switzerland) by the SuperPicture polymer detection. Following incubation with primary antibody, sections were treated with biotinylated rabbit anti-mouse immunoglobulins (at 1:200 dilution; DAKO, Carpinteria, CA) before the addition of streptavidin horseradish peroxidase conjugate (at 1:400 dilution; Zymed, San Francisco, CA). Chromogen signals were developed with diaminobenzidine-H2O2 substrate mixture. The percentage of positively stained tumor cells was scored as TMA, protein expressions were classified as Grade 1 (no staining), Grade 2 (1–9%) and Grade 3 (>10% of cells).

In-vitro cytotoxic assay

The cytotoxic effect of Etoposide (ABIC, Israel) as a single agent and in combination with Doxorubicin (Ebewe Pharma, Austria) in 3 HCC cell lines, HKCI-1, -2 and -3, were studied and evaluated by the MTT assay (Sigma, St. Louis, MO). Approximately 4 × 103 cells/well of each cell line were seeded 24 hr before addition of Etoposide. Five replicates were analyzed for each concentration ranging from 0 to 345 μM. Cell viability was measured at 48 hr by the colorimetric product developed at 570 nm. The IC50 and IC20 concentrations were determined by the linear regression analysis using the Graphpad Prism 3.0 software (San Diego, CA).

In the combinatory application of Etoposide with Doxorubicin, cells were treated with IC20 concentration of Etoposide for 4 hr before the addition of sequential dilutions of Doxorubicin ranging from 0 to 367 μM. After 44 hr, MTT assay was performed and the IC50 value determined was compared to treatment with Doxorubicin alone. Values reported were the mean of 3 independent experiments.

Statistical analysis

TOP2A mRNA expression in HCC tumors and paired adjacent non-tumoral livers were compared by the Student's paired t-test. Correlation of TOP2A mRNA levels with protein expressions was examined by the Spearman's rho test. The Pearson's χ2 test was used to examine the TOP2A protein scores with clinicopathological features including tumor stagings, histological differentiations, presence of macro- or microvascular invasions and patients' demographics. In the Phase III clinical study, overall survival was measured from the date of randomization to the date of death or last contact if patient was still alive. All data were censored on May 31, 2004. Immunohistochemical expressions of TOP2A, P-gp and MPR1 were studied for correlation with chemotherapy responsiveness and survival of patients. A stepwise logistic regression analysis was applied to examine the association of independent marker with response to chemotherapy. Overall survival was analyzed by the Kaplan-Meier method. A p-value <0.05 was considered to be statistically significant. All statistical analysis was performed using SPSS for Windows 10.0, SAS version 8.2 and Graphpad Prism 3.0.

Results

  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information

Candidate Prot-oncogenes in causal regional gains

High-resolution array-based transcriptional mapping revealed a number of aberrantly overexpressed genes in the causative genomic regions of HCC. In 22 HCC cell lines studied, modulators or transducers of various signalling systems (14-3-3 zeta; IL11; GNA13; GRB2), transcriptional regulators (C-MYC; SP2, SPIB; SUMO2), protein stabilizers (heat shock protein 70; DNAJC5) and inducers of cell proliferation (CSE1L; HDGF) were suggested (Supp. Info. Table I). Of interest, several cell cycle related genes (TOP2A, CDC27 and TUBG1) were found to cluster on chr. 17q21 (Fig. 1). Also, few genes were found exclusively overexpressed in cases with copy number gains, e.g., the spindle assembler, AURKA, cytoskeletal component, SGCA, regulator of fibrinolysis, SERPINE1 and ABC transporter, CFTR. Other candidates such as the transcriptional regulator, ZNF229, export receptor, CSE1L and matrix adhesion molecule, ITGA3 were found to be up-regulated in both cell lines categories with and without regional gains.

thumbnail image

Figure 1. Candidate genes up-regulation in regional Chr. 17q21-q25 gain. Hybridized CGH image indicating genomic gains of chr. 17q21-q25 is shown alongside signal ratio plot. Array-based transcriptional mapping indicated a cluster of up-regulated genes on regional 17q21-q25 gain. High expressions of TOP2A and SGCA were suggested. The normalized intensity of relative copy gains is shown.

Download figure to PowerPoint

TOP2A expressions in HCC

Distinct overexpression of TOP2A identified from transcriptional mapping has prompted our further investigations on its potential value as biomarker in HCC. Based on microarray, up-regulations of TOP2A were suggested in 14/22 cell lines, among which 9 cell lines displayed regional 17q21-q25 gain. Validative measurements of TOP2A mRNA transcripts by qRT-PCR suggested complete concordance with array findings in 14/14 cell lines (Fig. 2a). Increased expressions of TOP2A in 3 additional cell lines (HKCI-1, Hep3B and Huh7) were also suggested from qRT-PCR, albeit not indicated from array hybridization. The possible role of DNA copy gains in the induction of TOP2A expression was also investigated by FISH. Copy gains of TOP2A were confirmed in 9/9 cell lines with 17q gain (Fig. 2b).

thumbnail image

Figure 2. Validative analysis of TOP2A in HCC cell lines. (a) Quantitative analysis of TOP2A transcriptions by qRT-PCR in HCC cell lines suggested a concordant increased in mRNA expression with microarray findings. (b, c) FISH analysis indicated copy gains of the TOP2A gene in cell lines HKCI-4 and HKCI-5 that exhibited increased TOP2A expressions. Dual-color FISH was performed with TOP2A probe labeled as green and internal reference probe as red.

Download figure to PowerPoint

By qRT-PCR, we further examined the TOP2A mRNA levels in HCC and adjacent non-tumoral liver, which is also often considered the premalignant lesion of HCC. A significant level of TOP2A mRNA was suggested in tumors (median 13.46, quartiles 3.14–28.06) relative to non-tumoral liver (median 0.27, 0.15–1.47) (n = 30; paired t-test p = 0.0018) (Fig. 3a). A corresponding translated TOP2A protein was also confirmed by immunohistochemical staining, where a positive correlation with mRNA levels was suggested (n = 23; r = 0.612, p = 0.002) (Fig. 3b).

thumbnail image

Figure 3. (a) TOP2A expressions in primary HCC and adjacent non-tumoral liver. Quantitative RT-PCR indicated significant TOP2A up-regulations in HCC tumors compared to the adjacent putative premalignant non-tumoral livers. (b) Correlation of TOP2A mRNA expressions with protein levels. A positive correlation of mRNA expressions with TOP2A protein levels was suggested.

Download figure to PowerPoint

Large-scale immunohistochemical analysis of TOP2A expression was performed on a Tissue Microarray that contained 172 early resectable HCC tumors and paired adjacent non-tumoral livers (Table II). In agreement with mRNA findings, distinct TOP2A protein stainings were suggested in tumors compared to adjacent non-tumoral livers (Fig. 4). In the estimation of cells positive for the TOP2A nuclear staining, 32% of cases showed absent of expression, whereas Grades 2 and 3 scorings were suggested in 50% and 18% of cases, respectively. Further correlative analysis of TOP2A protein levels with clinicopathological features suggest high TOP2A protein score (Grade 3) to be significantly associated with poorly differentiated histology (p < 0.001), microvascular invasion (p = 0.004) and an early age onset of HCC (≤40 yrs; p = 0.007) (Fig. 5).

thumbnail image

Figure 4. Immunohistochemical analysis of TOP2A protein expressions in primary HCC and paired adjacent non-tumoral liver. Upper panel (a–d) histological features of HCC (a, b) and paired non-tumoral cirrhotic liver (c, d). Haematoxylin & eosin stainings of a & c at original magnification ×100; b & d, at original magnification ×400. Lower panel (e–h). Immunohistochemical staining of TOP2A in HCC (e, f) and paired non-tumoral liver (g, h). Diffused and strong nuclear staining of TOP2A (Grade 3) is observed in the HCC tissue while the adjacent non-tumoral hepatocytes in the regenerative nodule are negative. (e & g, TOP2A immunohistochemical stain, original magnification ×100; f & h, original magnification ×400).

Download figure to PowerPoint

thumbnail image

Figure 5. Correlation of TOP2A expressions with clinicopathologic features. Tissue microarray analysis indicated high TOP2A protein score (Grade 3) in association with (i) early age onset of HCC, *p = 0.003; (ii) progressive advancement of histological differentiation, **p < 0.001; and (iii) the presence of microvascular invasion, *p = 0.004.

Download figure to PowerPoint

Indicator of chemoresistance and survival

Of the 148 advance inoperable HCC patients recruited from the Phase III clinical study, 73 patients developed progressive disease during chemotherapy and were classified as the “chemotherapy resistant” group. There were 23 partial responders and 52 stable diseases; together they were classified as the “chemotherapy nonresistance” group. The overall median survival was 7.9 months (range 6.4–10.8). Patient characteristics are illustrated in Table I, which are similar to the reported Phase III study.7

Immunohistochemical stainings of 148 prechemotherapy biopsies indicated Grade 3 (>10% of cells) expressions of MRP1, P-gp and TOP2A in 65%, 54% and 30% of patients, respectively. Figure 6 shows examples of immunohistochemical results on MRP1, P-gp and TOP2A. Statistical correlations did not suggest expressions for MRP1 and P-gp in association with chemoresponses nor survival. However, a strong association for high TOP2A expressions with chemoresistance (p = 0.0289; odds ratio for resistance = 2.245, 95% CI 1.087–4.635) (Fig. 7) and shorter patient survivals (p < 0.0001) was demonstrated. Figure 8 shows the survival curves of studied population according to TOP2A, MRP1 and P-gp expressions.

thumbnail image

Figure 6. Immunohistochemical analysis of TOP2A, P-gp and MRP1 in HCC biopsies. (a, b) Immunohistochemical analysis of P-gp showed cannicular-staining pattern. (c, d) MRP1 showed predominant cytoplasmic staining. (e, f) TOP2A showed strong nuclear staining. Representative staining of Grade 2 scores shown in a, c and e, and Grade 3 scores in b, d and f. (×400 original magnification).

Download figure to PowerPoint

thumbnail image

Figure 7. Expression of TOP2A, P-gp and MRP1 in chemotherapy resistant and non-resistant patients. Immunohistochemical analysis on 148 HCC biopsies from a Phase III randomized trial7 indicated high-grade TOP2A expressions in association with chemotherapy resistance. No significant differences (N.S.) were suggested between Grade 3 and Grade 1–2 expressions of P-gp and MRP1.

Download figure to PowerPoint

thumbnail image

Figure 8. TOP2A, P-gp and MRP1 expressions in association with patient survival. Kaplan-Meier curves of the overall survival for patients depending on TOP2A, P-gp and MRP1 expressions. High-grade TOP2A expressions in patients (solid line) showed significantly worst overall survivals than low Grade 1–2 (dotted line) (p < 0.0001). Differences in patients' survival were not observed between Grade 3 and Grade 1–2 expressions of P-gp and MRP1.

Download figure to PowerPoint

Combinatory effect of TOP2A targeting and doxorubicin

Etoposide can interrupt the activity of DNA topoisomerase II by suppressing the enzyme mediated DNA cleavage. Doxorubicin, on the other hand, is a DNA intercalator that is currently the first-line cytotoxic agent for HCC patients. We examined the effect of Etoposide as a single agent and in combination with Doxorubicin on 3 HCC cell lines, HKCI-1, HKCI-2 and HKCI-3. These cell lines displayed TOP2A overexpressions by >10-fold compared to normal liver controls. A dosage-dependent inhibition on cell viability by Etoposide alone was suggested in all 3 cell lines, where the IC20 values determined ranged from 68 to 120 μM. When Etoposide at IC20 concentrations was introduced in conjunction with Doxorubicin, an enhanced combinatory effect was readily observed. A 10-fold reduction in the IC50 value of Doxorubicin was suggested in HKCI-1, whereas ∼3.5-fold decrease was suggested in both HKCI-2 and HKCI-3 (Fig. 9).

thumbnail image

Figure 9. Combinatory effect of TOP2A targeting and cytotoxic treatment. A dose-dependent effect of single agent Etoposide (Etop) and Doxorubicin (Doxo) in cell lines HKCI-1, -2 and -3 is shown. In the combinatory application of Etop and Doxo, it was found that Etop at IC20 concentrations could sensitise HCC cells to doxorubicin-induced cell deaths.

Download figure to PowerPoint

Discussion

  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information

Gene expression profilings have successfully provided new insights into the molecular pathogenesis and classifications of human malignancies.22–24 Array-based transcriptional mapping further offers the feasibility to correlate chromosomal aberrations with gene expression data in identifying novel genes.25, 26 Here, we examined 7 regional gains that are of pivotal importance to the causation and maintenance of HCC for affected proto-oncogenes. Transcriptional mapping indicated a number of aberrantly expressed candidates in the causative loci. These included 14-3-3 zeta, PVT1 and C-MYC at 8q22-q24, S100A4 and HDGF on 1q21-q24, and STK6 on 20q12-q13. Of interest was cell cycle related genes on chr. 17q21 (TOP2A, CDC27 and TUBG1) were found to be concurrently up-regulated. This might have implications in the concerted actions of genes induced from the proximal 17q gain in the uncontrolled cell growth. In line with our previous bioinformatic study on CGH events, which suggested gains of 17q in the progression of HCC,12 studies on gastric cancer, prostate carcinoma and neuroblastoma have also long postulated on genes harboring on the proximal 17q12-q21 to play an important role in tumor progressions.27–29 In this respect, distinct overexpression of TOP2A identified at chr. 17q21.2 was further investigated for its potential clinical value in HCC.

The TOP2A gene encodes a DNA topoisomerase, an enzyme that controls and alters the topologic states of DNA during transcription. Despite a role in DNA metabolism, in-vitro studies have indicated that expression of TOP2A in tumors is less dependent on the proliferation state of malignant cells.30 Expression of TOP2A has also been demonstrated in breast, colon, ovarian and small cell lung cancers to be a valuable prognostic marker for tumor advancements, recurrences and predictor of poorer survival.31–34 In HCC, although common up-regulations of TOP2A have been suggested,35, 36 a systematic investigation of TOP2A as a biomarker and target in chemosensitization has not been described. In this study, we found a strong positive relationship between TOP2A mRNA expressions with translated protein levels. This finding has invariably facilitated our further large-scale evaluation on the prognostic significance of TOP2A by immunohistochemical analysis. By Tissue Microarray analysis, we found high protein expressions of TOP2A correlated with advance tumor histology, microvascular invasion and the likely indication of an early age onset. As vascular invasion frequently occurs in HCC and holds prognostic implications for tumor invasions and metastasis,37 our finding may be interpretation as TOP2A expressions correlate with a more aggressive tumor phenotype.

The emergence of drug resistance presents a major obstacle in cancer chemotherapy for HCC. With the accessibility of pretreatment biopsies from HCC patients who had undergone doxorubicin-containing chemotherapy, immunohistochemical staining of biomarkers in pretreatment tumour biopsies has allowed our correlative analysis with disease outcome. We assessed the protein expressions of TOP2A, P-gp and MRP1 in relation to survival of this patient population and responsiveness to chemotherapy. Overexpressions of both P-gp and MRP1 have been indicated as prognostic indicators in the induction of chemotherapy resistance, disease relapse and overall survival.38, 39 However, in this study, we were unable to establish a causative link between the increased protein efflux activities of P-gp and MRP1 with drug resistance and disease outcome. Instead, prognostic significance was indicated for TOP2A, where high protein score (Grade 3) correlated with nonresponsiveness to chemotherapy and early disease-related deaths. Using in-vitro experimental models, increased TOP2A expression has been shown to confer resistance to fractionated radiation and chemotherapeutic agents in small-cell lung cancer cells,40 and in the acquired doxorubicin resistance behavior of HCC cell lines.41 Our present study thus provides further support for the prognostic significance of TOP2A expression in HCC patients.

In addition to its role in regulating cellular replication, TOP2A is also a molecular target for several anti-cancer chemotherapeutic agents and a variety of mutations in this gene has been described in the development of drug resistance.42, 43 It is know that the activity of DNA topoisomerase II can be interrupted by enzyme binders (e.g., Etoposide) or DNA lesions (e.g., abasic sites) to produce topoisomerase II-mediated DNA damage. In-vitro studies have also demonstrated that the forced expressions of topoisomerase by ectopic transfection could enhance the therapeutic effect of Etoposide in drug-resistant breast and brain cancer cell lines.44, 45 In this study, we showed that Etoposide could sensitize HCC cells to doxorubicin-induced cell death. In HCC cell lines expressing increased TOP2A, Etoposide at low concentrations (IC20 doses) reduced the doxorubicin IC50 dosage by ∼3.5-fold to as much as 10-fold compared to doxorubicin alone. Our data suggested both enhanced and synergistic effects could be found with the combinatorial use of Etoposide and doxorubicin. In view of concerns over the toxicities related to the use of doxorubicin,7, 46 our finding might hold value in the further development of combinatory therapies for HCC patients.

In conclusions, the present study demonstrated the effectiveness in the integrated approach of chromosomal aberrations with genes expression mapping in underpinning candidate genes. Our study also highlights the clinical usefulness in the complementary use of TMA in the validation of molecular markers. Preliminary investigation on the relationship of TOP2A copy number and gene expression suggested a strong predisposing role of FISH-derived copy gains in gene up-regulations. Given that TOP2A expressions correlated with more aggressive HCC tumor phenotype and patient responsiveness to doxorubicin-based therapy, future development of FISH testing and/or immunohistochemical staining for TOP2A status may aid clinical practice in highlighting patients whom are likely to be resistant to conventional cytotoxic therapy. Furthermore, in the light of new clinical trials targeting molecular abnormalities in HCC,47 studies on effective combinatory therapy including reduced toxicities may hold benefit in the management of patients with unresectable hepatocellular carcinoma.

Acknowledgements

  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information

The authors would like to thank Prof. Jeremy Squire and Dr. Ben Beheshti for their technical support in microarray development and analytical software.

References

  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information
  • 1
    Hong Kong Hospital Authority. Cancer incidence and mortality in Hong Kong 1999. Hong Kong Cancer Registry, Hong Kong, 2002.
  • 2
    Parkin DM,Stjernsward J,Muir CS. Estimates of the worldwide frequency of twelve major cancers. Bull World Health Organ 1984; 62: 16382.
  • 3
    McGlynn KA,Tarone RE,El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2006; 15: 1198203.
  • 4
    Greten TF,Papendorf F,Bleck JS,Kirchhoff T,Wohlberedt T,Kubicka S,Klempnauer J,Galanski M,Manns MP. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 2005; 92: 18628.
  • 5
    Nerenstone SR,Ihde DC,Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 1988; 15: 131.
  • 6
    Hochster HS,Green MD,Speyer J,Fazzini E,Blum R,Muggia FM. 4-Epidoxorubicin (Epirubicin): activity in hepatocellular carcinoma. J Clin Oncol 1985; 11: 153540.
  • 7
    Yeo W,Mok TS,Zee B,Leung WT,Lau PBS,Lau WY,Koh J,Mo MKF,Yu S,Chan AT,Hui P,Ma B, et al. Phase III study of adriamycin versus cisplatin/interferon a-2b/adriamycin/ fluorouracil combination chemotherapy for inoperable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 15328.
  • 8
    Slamon DJ,Leyland-Jones B,Shak S,Fuchs H,Paton V,Bajamonde A,Fleming T,Eiermann W,Wolter J,Pegram M,Baselga J,Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 78392.
  • 9
    Ross JS,Fletcher JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol 1999; 9: 12538.
  • 10
    Endicott J,Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 1989; 58: 13771.
  • 11
    Cole SP,Bhardwaj G,Gerlach JH,Mackie JE,Grant CE,Almquist KC,Stewart AJ,Kurz EU,Duncan AM,Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 16504.
  • 12
    Poon TC,Wong N,Lai PB,Rattray M,Johnson PJ,Sung JJ. A tumor progression model for hepatocellular carcinoma—bioinformatic analysis of genomic data. Gastroenterology 2006; 131: 126270.
  • 13
    Niketeghad F,Decker HJ,Caselmann WH,Lund P,Geissler F,Dienes HP,Schirmacher P. Frequent genomic imbalances suggest commonly altered tumour genes in human hepatocarcinogenesis. Br J Cancer 2001; 85: 697704.
  • 14
    Guan XY,Fang Y,Sham JS,Kwong DL,Zhang Y,Liang Q,Li H,Zhou H,Trent JM. Recurrent chromosome alterations in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 2000; 29: 11016.
  • 15
    Wong N,Lai P,Lee SW,Fan S,Pang E,Liew CT,Zhong S,Lau LW,Johnson PJ. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size and cirrhosis. Am J Pathol 1999; 154: 3743.
  • 16
    Pollack JR,Sorlie T,Perou CM,Rees CA,Jeffrey SS,Lonning PE,Tibshirani R,Botstein D,Borresen-Dale AL,Brown PO. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 2002; 99: 129638.
  • 17
    Heidenblad M,Lindgren D,Veltman JA,Jonson T,Mahlamaki EH,Gorunova L,van Kessel AG,Schoenmakers EF,Hoglund M. Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications. Oncogene 2005; 24: 1794801.
  • 18
    Wong N,Chan KY,Macgregor PF,Lai PB,Squire JA,Beheshti B,Albert M,Leung TW. Transcriptional profiling identifies gene expression changes associated with α-interferon resistance in hepatitis C-related hepatocellular carcinoma cells. Clin Cancer Res 2005; 11: 131926.
  • 19
    Chan KY,Wong N,Lai PB,Squire JA,Macgregor PF,Beheshti B,Albert M,To KF,Johnson PJ. Transcriptional profiling on chromosome 19p indicated frequent down-regulation of ACP5 expression in hepatocellular carcinoma. Int J Cancer 2005; 114: 9028.
  • 20
    Pang E,Wong N,Lai PB,To KF,Lau WY,Johnson PJ. Consistent chromosome 10 rearrangements in four newly established human hepatocellular carcinoma cell lines. Genes Chromosomes Cancer 2002; 33: 1509.
  • 21
    World Health Organization. World Health Organization Handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
  • 22
    Petty RD,Nicolson MC,Kerr KM,Collie-Duguid E,Murray GI. Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application. Clin Cancer Res 2004; 10: 323748.
  • 23
    Lapointe J,Li C,Higgins JP,van de Rijn M,Bair E,Montgomery K,Ferrari M,Egevad L,Rayford W,Bergerheim U,Ekman P,DeMarzo AM, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101: 8116.
  • 24
    Hedenfalk I,Ringner M,Ben-Dor A,Yakhini Z,Chen Y,Chebil G,Ach R,Loman N,Olsson H,Meltzer P,Borg A,Trent J. Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci USA 2003; 100: 25327.
  • 25
    Staub E,Grone J,Mennerich D,Ropcke S,Klamann I,Hinzmann B,Castanos-Velez E,Mann B,Pilarsky C,Brummendorf T,Weber B,Buhr HJ, et al. A genome-wide map of aberrantly expressed chromosomal islands in colorectal cancer. Mol Cancer 2006; 5: 144.
  • 26
    Reyal F,Stransky N,Bernard-Pierrot I,Vincent-Salomon A,de Rycke Y,Elvin P,Cassidy A,Graham A,Spraggon C,Desille Y,Fourquet A,Nos C, et al. Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes—a study of 130 invasive ductal breast carcinomas. Cancer Res 2005; 65: 137683.
  • 27
    Varis A,Wolf M,Monni O,Vakkari M-L,Kokkola A,Moskaluk C,Frierson H,Jr,Powell SM,Knuutila S,Kallioniemi A,El-Rifai W. Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res 2002; 62: 26259.
  • 28
    Plummer SJ,Paris MJ,Myles J,Tubbs R,Crowe J,Casey G. Four regions of allelic imbalance on 17q12-qter associated with high-grade breast tumors. Genes Chromosomes Cancer 1997; 20: 35462.
  • 29
    Bown N,Cotterill S,Lastowska M,O'Neill S,Pearson AD,Plantaz D,Meddeb M,Danglot G,Brinkschmidt C,Christiansen H,Laureys G,Speleman F. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999; 340: 195461.
  • 30
    Stacey DW,Hitomi M,Chen G. Influence of cell cycle and oncogene activity upon topoisomerase IIα expression and drug toxicity. Mol Cell Biol 2000; 20: 912737.
  • 31
    Fritz P,Cabrera CM,Dippon J,Gerteis A,Simon W,Aulitzky WE,van der Kuip H. c-erbB2 and topoisomerase IIα protein expression independently predict poor survival in primary human breast cancer: a retrospective study. Breast Cancer Res 2005; 7: R374R384.
  • 32
    Dingemans AM,Witlox MA,Stallaert RA,van der Valk P,Postmus PE,Giaccone G. Expression of DNA topoisomerase IIα and topoisomerase IIβ genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res 1999; 5: 204858.
  • 33
    Lazaris AC,Kavantzas NG,Zorzos HS,Tsavaris NV,Davaris PS. Markers of drug resistance in relapsing colon cancer. J Cancer Res Clin Oncol 2002; 128: 11418.
  • 34
    Costa MJ,Hansen CL,Holden JA,Guinee D, Jr. Topoisomerase II alpha: prognostic predictor and cell cycle marker in surface epithelial neoplasms of the ovary and peritoneum. Int J Gynecol Pathol 2000; 19: 24857.
  • 35
    Paradis V,Bièche I,Dargère D,Laurendeau I,Laurent C,Sage PB,Degott C,Belghiti J,Vidaud M,Bedossa P. Molecular profiling of hepatocellular carcinomas (HCC) Using a large-scale real-time RT-PCR approach: determination of a molecular diagnostic index. Am J Pathol 2003; 163: 73341.
  • 36
    Xu XR,Huang J,Xu ZG,Qian BZ,Zhu ZD,Yan Q,Cai T,Zhang X,Xiao HS,Qu J,Liu F,Huang QH, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA 2001; 98: 1508994.
  • 37
    Poon RT,Fan ST. Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. Surg Oncol Clin N Am 2003; 12: 3550.
  • 38
    Schaich M,Soucek S,Thiede C,Ehninger G,Illmer T,SHG AML, 96 Study Group.MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 2005; 128: 32432.
  • 39
    Yakirevich E,Sabo E,Naroditsky I,Sova Y,Lavie O,Resnick MB. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol Oncol 2006; 100: 1529.
  • 40
    Henness S,Davey MW,Harvie RM,Davey RA. Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase IIalpha expression. Int J Radiat Oncol Biol Phys 2002; 54: 895902.
  • 41
    Pang E,Hu Y,Chan KY,Lai PB,Squire JA,Macgregor PF,Beheshti B,Albert M,Leung TW,Wong N. Karyotypic imbalances and differential genes expression in the acquired doxorubicin resistance phenotype of hepatocellular carcinoma cells. Lab Invest 2005; 85: 66474.
  • 42
    Capranico G,Zagotto G,Palumbo M. Development of DNA topoisomerase-related therapeutics: a short perspective of new challenges. Curr Med Chem Anticancer Agents 2004; 4: 33545.
  • 43
    Okada Y,Tosaka A,Nimura Y,Kikuchi A,Yoshida S,Suzuki M. Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha. Gene 2001; 272: 1418.
  • 44
    Asano T. Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide. Br J Cancer 1996; 73: 137380.
  • 45
    Zhou Z,Zwelling LA,Kawakami Y,An T,Kobayashi K,Herzog C,Kleinerman ES. Adenovirus-mediated human topoisomerase II alpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res 1999; 59: 461824.
  • 46
    Levine MN,Bramwell VH,Pritchard KI,Norris BD,Shepherd LE,Abu-Zahra H,Findlay B,Warr D,Bowman D,Myles J,Arnold A,Vandenberg T, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16: 26512658.
  • 47
    Thomas MB,Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005; 23: 8093108.

Supporting Information

  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
IJC_23968_sm_suppinfotable1.doc103KSupplemental Table1: Clusters of Up-regulated Genes in Common Regional Gains of HCC.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.